A clinical trial involving teriparatide was updated on June 11, 2026. The study, titled "Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid," is registered under identifier NCT03735537. It is listed as a Phase 4 trial. Its current status has been recorded as completed.
The trial evaluated the use of parathyroid hormone, specifically teriparatide, in combination with zoledronic acid for individuals with osteogenesis imperfecta. No results have been reported alongside this status update. This brief reflects only the status change and does not describe any outcomes, efficacy data, or safety findings from the trial.
Teriparatide is an approved compound. Its use in this study was investigated in a specific patient population and combination not necessarily reflective of standard approved use. Readers interested in the trial details, including its design and any future posted results, can consult the official listing at ClinicalTrials.gov under the identifier provided.
For more background on teriparatide, including its approved uses and general profile, see the compound overview.